瑞巴克福辛 (Rabacfosadine)
Rabacfosadine
別名: Tanovea-CA1 · GS-9219 · VDC-1101
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
各物種劑量
🌎 NA — North America🌍 EU — Europe
狗
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Lymphoma (B and T cell) and multiple myeloma | 0.82-1 mg/kg | IV | once every 21 days | over 30 min | 🌍 EU |
- Lymphoma (B and T cell) and multiple myeloma: Has been used in combination with doxorubicin at weeks 0, 6, 12 as part of an alternating protocol.
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
概覽
瑞巴克福辛 (Rabacfosadine) 是一種新型抗腫瘤藥物，主要用於獸醫學中治療犬淋巴瘤（B細胞和T細胞）及多發性骨髓瘤。
臨床警告： 本品為強效細胞毒性藥物，必須由受過專業訓練的人員遵循嚴格的化療安全指南進行配製與給藥。
作用機轉
Rabacfosadine is a prodrug of the nucleotide analogue PMEG (9-(2-phosphonylmethoxyethyl)guanine). Once converted, it acts by inhibiting DNA polymerases → preventing DNA synthesis → causing cytotoxicity and apoptosis in rapidly dividing cells, such as neoplastic lymphocytes.
安全性與警告
禁忌症
- Known hypersensitivity
- Pre-existing bone marrow suppression
- Liver dysfunction
- Known pulmonary disease
- Susceptibility to pulmonary fibrosis
不良反應
- Myelosuppression
- Gastrointestinal adverse events (including haemorrhagic gastroenteritis)
- Liver enzyme activity elevation
- Azotaemia
- Fever
- Weight loss
- Lethargy
- Dermatological signs
- Pulmonary fibrosis
- Injected sclera
- Urinary signs (proteinuria, glycosuria)
注意事項
Handling Precautions: Potent cytotoxic drug that should only be prepared and administered by trained personnel. See specialist texts for further advice on chemotherapeutic agents.
Clinical Pearl: Extreme caution is advised regarding pulmonary toxicity; patients should be carefully screened for pre-existing lung conditions before initiating therapy.
監測
- Complete Blood Count (CBC) for myelosuppression
- Liver enzyme activity
- Renal parameters (BUN, Creatinine) and Urinalysis (for proteinuria/glycosuria)
- Respiratory rate and effort (monitor for pulmonary fibrosis)
- Clinical signs of gastrointestinal toxicity
藥物動力學
吸收
Administered intravenously; 100% bioavailability.
分佈
Distributes to lymphoid tissues where it is loaded into target cells.
代謝
Acts as a prodrug; metabolized intracellularly to the active moiety PMEG and subsequently phosphorylated to the active PMEG diphosphate.
排除
Primarily eliminated via the kidneys.
過量
Information not provided in the monograph. Due to its cytotoxic nature, overdose is likely to cause severe myelosuppression, gastrointestinal toxicity, and potentially fatal pulmonary fibrosis. Aggressive supportive care and monitoring are indicated.
可用產品
劑型
- Injectable: Sterile lyophilized powder for reconstitution (8.2 mg/ml after reconstitution)
獸醫用
- Tanovea-CA1 (Sterile lyophilized powder)
各地核准狀態
Initially conditionally approved as Tanovea-CA1, now fully approved as Tanovea.
POM-V. Handled as a hazardous cytotoxic agent.
POM-V. Handled as a hazardous cytotoxic agent.
暫無法規資料: 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Sterile lyophilized powder for reconstitution before use. Reconstitute with 2 ml 0.9% NaCl.
飼主須知
本藥物是一種用於治療犬隻特定癌症（如淋巴瘤）的化療藥物。
- 排泄物處理： 由於這是化療藥物，請在治療後幾天內嚴格遵循獸醫的指示處理狗狗的尿液和糞便。
- 觀察症狀： 密切觀察狗狗是否有腸胃不適（嘔吐、腹瀉、食慾不振）、極度疲倦或呼吸改變（如咳嗽或呼吸急促）。
- 呼吸問題： > 如果您發現狗狗有任何呼吸困難，請立即聯繫獸醫，因為此藥物極少數情況下會導致肺部纖維化。
VetSheet 藥物參考供合格獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠商最新仿單。